Recent patents relating to HCV molecules like putative targets for therapeutic intervention.
In recent years, many pharmaceutical and biotechnology companies have shifted their drug development for infectious diseases from antibacterial to antiviral discovery. This trend reflects the large population involved in viral diseases, the need for chronic or long-term treatment, and significant unmet needs. In particular, human immunodeficiency virus, hepatitis C virus (HCV), and hepatitis B virus have been the focus of drug development, representing important areas of future growth. This report provides an overview of the most recent patents relating to HCV molecules as targets for therapeutic intervention, outlining the key drug targets and steps where pharmacological intervention can have a favorable therapeutic benefit. Historically, HCV drug development has been hampered by the lack of reliable cell culture systems and animal infection models. However, early research studies have identified new models of HCV infection, and the better acknowledgment of the viral lifecycle have allowed the identification of several highly promising targets, including protease, helicase, polymerase or inhibitors of virus attachment, which are considered drug candidates that can potentially change the treatment of HCV.
De Re
Valli
V
Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Aviano, Pordenone, Italy. vdere@cro.it
Sansonno
Domenico
D
De Paoli
Paolo
P
Geremia
Silvano
S
Gatti
Pietro
P
Caggiari
Laura
L
Simula
Maria P
MP
Toffoli
Giuseppe
G
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D016174:Hepacivirus / Q000378:metabolism*; D006526:Hepatitis C / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D010330:Patents as Topic; D014764:Viral Proteins / Q000037:antagonists & inhibitors*; D053585:Virus Attachment / Q000187:drug effects
D000998:Antiviral Agents; D014764:Viral Proteins